glp-1 obesity cardiovascular news How are drugs reshaping treatment for obesity, diabetes, and heart disease? GLP-1: A Game-Changer for Heart

Vessey MP, McPherson K, Villard-Mackintosh L, Yeates D

& Warren, K

Some research shows it may inhibit inflammatory cytokines (immune system molecules)

As an example of the structural electrostatic perspective, in 2021, a manually designed structural modification involving a Val27-Arg28 (Val33-Arg34 in PDB entry 4ZGM) exchange (V-R exchange) [43] was introduced into the backbone of semaglutide towards the enhancement of semaglutide-GLP-1R binding affinity (K d ) from 3.4 10 6 M at 37 C to 1.1 10 6 M at 37 C, where a newly established structure-stabilizing interfacial salt bridge was formed between Glu104 (A Glu 127 in PDB entry 4ZGM) of GLP-1R ECD and Arg27 (B Val 33 in PDB entry 4ZGM) of semaglutide, which is entirely due to the manually designed V-R exchange [43]

Up-regulation of peroxisome proliferator-activated receptors (PPAR) and PPAR messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-responsive adipose tissue-specific genes in the liver of obese diabetic mice